Nurix Stock Story


USD 15.99  0.98  5.77%   

It appears Nurix Therapeutics will continue to recover much faster as its share price surged up 5.13% today. The company current daily volatility is 7.25 percent, with a beta of 1.59 and an alpha of 0.37 over DOW. As many baby boomers are still indifferent towards stable market, it makes sense to break down Nurix Therapeutics. We will cover the possibilities of making Nurix Therapeutics into a steady grower in August.
Published over a month ago
View all stories for Nurix Therapeutics | View All Stories

Chances of Nurix Therapeutics to slide after the volatility rises

This firm conducts business under Healthcare sector and is part of Biotechnology industry.
One of the ways to look at asset utilization of Nurix is to check how much profit was generated for every dollar of assets it reports. Nurix Therapeutics secures a negative usage of assets of -20.39 %, losing $0.2 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Nurix Therapeutics shows how discouraging it operates for each dollar spent on its assets.
Investing in Nurix Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Nurix Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Nurix Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Nurix Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Nurix Therapeutics. Your research has to be compared to or analyzed against Nurix Therapeutics' peers to derive any actionable benefits. When done correctly, Nurix Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Nurix Therapeutics.

How important is Nurix Therapeutics's Liquidity

Nurix Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Nurix Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Nurix Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Nurix Therapeutics's total debt and its cash.

How does Nurix utilize its cash?

To perform a cash flow analysis of Nurix Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nurix Therapeutics is receiving and how much cash it distributes out in a given period. The Nurix Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Van Houte Hans of 120000 shares of Nurix Therapeutics subject to Rule 16b-3

Legal trades by Nurix Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Nurix insider trading alert for grant of employee stock option (right to buy) by Van Houte Hans, Chief Financial Officer, on 10th of August 2022. This event was filed by Nurix Therapeutics Inc with SEC on 2022-08-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Nurix Therapeutics

We consider Nurix Therapeutics somewhat reliable. Nurix Therapeutics has Sharpe Ratio of 0.0181, which conveys that the firm had 0.0181% of return per unit of risk over the last 3 months. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Nurix Therapeutics, which you can use to evaluate the future volatility of the firm. Please verify Nurix Therapeutics Downside Deviation of 7.08, risk adjusted performance of 0.0237, and Mean Deviation of 5.33 to check out if the risk estimate we provide is consistent with the expected return of 0.13%.

Our perspective of the current Nurix Therapeutics rise

Current Treynor Ratio is up to 0.04. Price may slide again.
As of the 4th of July, Nurix Therapeutics secures the Downside Deviation of 7.08, mean deviation of 5.33, and Risk Adjusted Performance of 0.0237. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nurix Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Nurix Therapeutics, which can be compared to its peers in the industry. Please verify Nurix Therapeutics information ratio and downside variance to decide if Nurix Therapeutics is priced some-what accurately, providing market reflects its recent price of 13.32 per share. Given that Nurix Therapeutics has jensen alpha of 0.3733, we recommend you to check Nurix Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Our Final Take On Nurix Therapeutics

While some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Nurix Therapeutics may offer a potential longer-term growth to investors. On the whole, as of the 4th of July 2022, our final 90 days buy vs. sell advice on the company is Hold. We believe Nurix Therapeutics is undervalued with low probability of financial unrest for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Nurix Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to